Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: Role of dysregulation of renal water transporters

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 10, 2013, Pages

  Zhou, Li ^a,b,c   Liu, Gang ^b   Jia, Zhanjun ^b   Yang, Kevin T ^b,c   Sun, Ying ^b   Kakizoe, Yutaka ^b   Liu, Mi ^c   Zhou, Shufeng ^d   Chen, Ren ^e   Yang, Baoxue ^a   Yang, Tianxin ^b,c  

^a PEKING UNIVERSITY   (China)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

db db; Nanoparticle; Plasma volume; PPAR ; Rosiglitazone

Indexed keywords

AQUAPORIN 2; AQUAPORIN 3; NANOPARTICLE; ROSIGLITAZONE; SODIUM ION; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; SODIUM PROTON EXCHANGE PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIURESIS; DOWN REGULATION; FLUID RETENTION; FLUORESCENCE; HEMATOCRIT; IMMUNOBLOTTING; LEAN BODY WEIGHT; MALE; MOUSE; MOUSE STRAIN; NATRIURESIS; NONHUMAN; PLASMA OSMOLALITY; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SODIUM URINE LEVEL; URINE VOLUME; WEIGHT GAIN;

EID: 84887588325     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00004.2013     Document Type: Article

References (30)

1. Anonymous. Pioglitazone PIA. Osaka, Japan: Takeda Pharmaceuticals.
2. Anonymous. Rosiglitazone PIA. Mumbai, India: GlaxoSmithKline Pharmaceuticals.
3. Arakawa K, Ishihara T, Aoto M, Inamasu M, Kitamura K, Saito A. An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin Exp Pharmacol Physiol 31: 8-13, 2004.
4. Beltowski J, Rachanczyk J, Wlodarczyk M. Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPAR Res 2013: 628628, 2013.
5. Borsting E, Cheng VP, Glass CK, Vallon V, Cunard R. Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney. Am J Physiol Renal Physiol 302: F540-F551, 2012.
6. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 23: 205-215, 2012.
7. Eisner C, Espey M, Ow H, Wang K, Wesner U, Schnermann J. Measurement of plasma volume using nanoparticles in mice. FASEB J 23: 804819, 2009.
8. GlaxoSmithKline Pharmaceuticals. Advandia (Rosiglitazone Maleate). Research Triangle Park, NC: NGPPI.
9. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11: 861-866, 2005.
10. Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK. Recent developments and biological activities of thiazolidinone derivatives: a review. Bioorg Med Chem 20: 3378-3395, 2012.
11. Jia Z, Aoyagi T, Kohan DE, Yang T. mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. Am J Physiol Renal Physiol 299: F155-F166, 2010.
12. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 78: 1088-1091, 2003.
13. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83: 813-819, 1995.
14. Kung J, Henry RR. Thiazolidinedione safety. Expert Opin Drug Saf 11: 565-579, 2012.
15. Mudaliar S, Chang AR, Aroda VR, Chao E, Burke P, Baxi S, Griver KA, O'Connor DT, Henry RR. Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes. Diabetes Obes Metab 12: 133-138, 2010.
16. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941-2948, 2003.
17. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 22: 924-929, 2002.
18. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007.
19. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134: 61-71, 2001.
20. Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2: 61-66, 2005.
21. Pickavance LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JP. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 128: 1570-1576, 1999.
22. Riazi S, Khan O, Tiwari S, Hu X, Ecelbarger CA. Rosiglitazone regulates ENaC and Na-K-2Cl cotransporter (NKCC2) abundance in the obese Zucker rat. Am J Nephrol 26: 245-257, 2006.
23. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 117: 2791-2801, 2007.
24. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activates renal sodium-and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 308: 426-433, 2004.
25. Takazawa T, Yamauchi T, Tsuchida A, Takata M, Hada Y, Iwabu M, Okada-Iwabu M, Ueki K, Kadowaki T. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes. J Biol Chem 284: 30049-30057, 2009.
26. Tiwari S, Blasi ER, Heyen JR, McHarg AD, Ecelbarger CM. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats. Pharmacol Res 57: 383-392, 2008.
27. Viswanathan V, Mohan V, Subramani P, Parthasarathy N, Subramaniyam G, Manoharan D, Sundaramoorthy C, Gnudi L, Karalliedde J, Viberti G. Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes. Clin J Am Soc Nephrol 8: 225-232, 2012.
28. Wang F, Aleksunes LM, Reagan LA, Vergara CM. Management of rosiglitazone-induced edema: two case reports and a review of the literature. Diabetes Tech Therap 4: 505-514, 2002.
29. Yang T. Kidney-specific gene targeting: insight into thiazolidinedioneinduced fluid retention. Nephrology (Carlton) 11: 201-206, 2006.
30. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102: 9406-9411, 2005.